Thomas Wurdinger
Overview
Explore the profile of Thomas Wurdinger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
124
Citations
8676
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Glogovitis I, DAmbrosi S, Antunes-Ferreira M, Chiogna M, Yahubyan G, Baev V, et al.
Noncoding RNA
. 2025 Feb;
11(1).
PMID: 39997617
Liquid biopsy has gained significant attention as a non-invasive method for cancer detection and monitoring. IsomiRs and tRNA-derived fragments (tRFs) are small non-coding RNAs that arise from non-canonical microRNA (miRNAs)...
2.
Scheepbouwer C, Aparicio-Puerta E, Gomez-Martin C, van Eijndhoven M, Drees E, Bosch L, et al.
bioRxiv
. 2024 May;
PMID: 38765958
Small extracellular vesicles (sEVs) are heterogenous lipid membrane particles typically less than 200 nm in size and secreted by most cell types either constitutively or upon activation signals. sEVs isolated...
3.
Dusoswa S, Verhoeff J, van Asten S, Lubbers J, van den Braber M, Peters S, et al.
Front Immunol
. 2024 Feb;
15:1343484.
PMID: 38318180
Background: Glioblastomas manipulate the immune system both locally and systemically, yet, glioblastoma-associated changes in peripheral blood immune composition are poorly studied. Age and dexamethasone administration in glioblastoma patients have been...
4.
Giczewska A, Pastuszak K, Houweling M, Abdul K, Faaij N, Wedekind L, et al.
Neurooncol Adv
. 2023 Dec;
5(1):vdad134.
PMID: 38047207
Background: In recent years, drug combinations have become increasingly popular to improve therapeutic outcomes in various diseases, including difficult to cure cancers such as the brain cancer glioblastoma. Assessing the...
5.
Kanev G, Zhang Y, Kooistra A, Bender A, Leurs R, Bailey D, et al.
PLoS Comput Biol
. 2023 Sep;
19(9):e1011301.
PMID: 37669273
Many therapies in clinical trials are based on single drug-single target relationships. To further extend this concept to multi-target approaches using multi-targeted drugs, we developed a machine learning pipeline to...
6.
Eslami-S Z, Cortes-Hernandez L, Glogovitis I, Antunes-Ferreira M, DAmbrosi S, Kurma K, et al.
Front Cell Dev Biol
. 2023 Aug;
11:1209846.
PMID: 37601099
Platelets are active players in hemostasis, coagulation and also tumorigenesis. The cross-talk between platelets and circulating tumor cells (CTCs) may have various pro-cancer effects, including promoting tumor growth, epithelial-mesenchymal transition...
7.
Houweling M, Giczewska A, Abdul K, Nieuwenhuis N, Kucukosmanoglu A, Pastuszak K, et al.
Neurooncol Adv
. 2023 Jul;
5(1):vdad073.
PMID: 37455945
Background: IDH-wildtype glioblastoma (GBM) is a highly malignant primary brain tumor with a median survival of 15 months after standard of care, which highlights the need for improved therapy. Personalized...
8.
Arkani M, Kianzad A, Jansen S, Smit J, Post E, Ramaker J, et al.
J Am Heart Assoc
. 2023 Jun;
12(13):e028447.
PMID: 37345802
Background Appropriate treatment of pulmonary hypertension (PH) is critically dependent on accurate discrimination between pre- and postcapillary PH. However, clinical discrimination is challenging and frequently requires a right heart catheterization....
9.
Antunes-Ferreira M, DAmbrosi S, Arkani M, Post E, In t Veld S, Ramaker J, et al.
Sci Rep
. 2023 Jun;
13(1):9359.
PMID: 37291189
Liquid biopsy approaches offer a promising technology for early and minimally invasive cancer detection. Tumor-educated platelets (TEPs) have emerged as a promising liquid biopsy biosource for the detection of various...
10.
Muller M, Best M, van der Noort V, Hiltermann T, Niemeijer A, Post E, et al.
Tumour Biol
. 2023 Jun;
46(s1):S327-S340.
PMID: 37270827
Background: Anti-PD-(L)1 immunotherapy has emerged as a promising treatment approach for non-small cell lung cancer (NSCLC), though the response rates remain low. Pre-treatment response prediction may improve patient allocation for...